New York, August 21, 2024 - PRISM MarketView - Bright Green Corporation (Nasdaq: BGXX) a pioneer in growing and manufacturing Schedule I, the most stringent category of restricted drug substances and plant-based psychedelics, has teamed up with Benuvia Pharmaceuticals.
The collaboration with Benuvia, a ground-breaking producer of pharmaceutical cannabinoids and psychedelic compounds in development for therapeutic purposes makes clear Bright Green’s commitment to sourcing clean label American organic materials for the pharma sector and will supply Benuvia with approved marijuana extracts and plant-based psychedelics.
Bright Green is one of only a U.S few vendors to supply DEA-controlled substances and aims to lead the domestic botanical supply market. This strategy supports a global trend in which national and international markets alike are demanding cannabinoids and psychedelic compounds for therapeutic applications.
The Drug Enforcement Administration (DEA) recently completed its annual operational procedures for Schedule I and II drug cultivation and manufacturing in July. Bright Green has successfully met these standards and is now positioned to begin operations, providing necessary materials to the pharmaceutical industry.
In the year ahead, Bright Green remains focused on financing and raw material supply agreements to further enhance its position within the rapidly evolving pharmaceutical industry.
ABOUT BENUVIA
Benuvia Operations, LLC is a pioneering leader in the research, development, and commercialization of innovative pharmaceutical products across a wide range of therapeutic areas. Benuvia is committed to improving patient outcomes through rigorous scientific study and quality manufacturing practices. With FDA registration, DEA licensing, and cGMP certification, Benuvia operates at the forefront of the pharmaceutical industry. Benuvia’s flagship product, SYNDROS, is an FDA-approved medication used for the treatment of anorexia associated with weight loss in patients with AIDS and for managing chemotherapy-induced nausea and vomiting. To learn more, visit www.benuvia.com.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities